Applied Therapeutics (APLT) Expected to Announce Quarterly Earnings on Wednesday

Applied Therapeutics (NASDAQ:APLT) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.42 million for the quarter.

Applied Therapeutics Trading Up 6.6%

Applied Therapeutics stock opened at $0.47 on Tuesday. The firm has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.45. The firm has a market capitalization of $66.54 million, a PE ratio of -1.09 and a beta of 1.97. Applied Therapeutics has a 12-month low of $0.30 and a 12-month high of $10.62.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on APLT shares. Royal Bank Of Canada restated a “sector perform” rating and issued a $1.50 target price on shares of Applied Therapeutics in a report on Wednesday, May 14th. Wall Street Zen upgraded shares of Applied Therapeutics to a “sell” rating in a report on Saturday, July 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Applied Therapeutics has an average rating of “Hold” and an average price target of $6.10.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Applied Therapeutics stock. AQR Capital Management LLC purchased a new position in Applied Therapeutics Inc. (NASDAQ:APLT) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 572,311 shares of the company’s stock, valued at approximately $280,000. AQR Capital Management LLC owned 0.40% of Applied Therapeutics at the end of the most recent reporting period. Institutional investors own 98.31% of the company’s stock.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.